| Comprehensive genomic characterization defines human glioblastoma genes and core pathways Cancer Genome Atlas Research Network Tissue source sites: Duke University ... Nature 455 (7216), 1061-1068, 2008 | 7599 | 2008 |
| The somatic genomic landscape of glioblastoma CW Brennan, RGW Verhaak, A McKenna, B Campos, H Noushmehr, ... cell 155 (2), 462-477, 2013 | 5254 | 2013 |
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis HS Phillips, S Kharbanda, R Chen, WF Forrest, RH Soriano, TD Wu, ... Cancer cell 9 (3), 157-173, 2006 | 3634 | 2006 |
| A randomized trial of bevacizumab for newly diagnosed glioblastoma MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ... New England Journal of Medicine 370 (8), 699-708, 2014 | 3095 | 2014 |
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma H Noushmehr, DJ Weisenberger, K Diefes, HS Phillips, K Pujara, ... Cancer cell 17 (5), 510-522, 2010 | 2802 | 2010 |
| Comprehensive molecular characterization of urothelial bladder carcinoma Cancer Genome Atlas Research Network Nature 507 (7492), 315, 2014 | 2743 | 2014 |
| DNA methylation-based classification of central nervous system tumours D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ... Nature 555 (7697), 469-474, 2018 | 2525 | 2018 |
| Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma M Ceccarelli, FP Barthel, TM Malta, TS Sabedot, SR Salama, BA Murray, ... Cell 164 (3), 550-563, 2016 | 2108 | 2016 |
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma D Sturm, H Witt, V Hovestadt, DA Khuong-Quang, DTW Jones, ... Cancer cell 22 (4), 425-437, 2012 | 2021 | 2012 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1935* | 2020 |
| The transcriptional network for mesenchymal transformation of brain tumours MS Carro, WK Lim, MJ Alvarez, RJ Bollo, X Zhao, EY Snyder, EP Sulman, ... Nature 463 (7279), 318-325, 2010 | 1415 | 2010 |
| Glioma M Weller, W Wick, K Aldape, M Brada, M Berger, SM Pfister, R Nishikawa, ... Nature reviews Disease primers 1 (1), 1-18, 2015 | 1354 | 2015 |
| Epidemiology and molecular pathology of glioma JA Schwartzbaum, JL Fisher, KD Aldape, M Wrensch Nature clinical practice Neurology 2 (9), 494-503, 2006 | 1280 | 2006 |
| Structure and mechanism of interleukin-lβ converting enzyme KP Wilson, JAF Black, JA Thomson, EE Kim, JP Griffith, MA Navia, ... Nature 370 (6487), 270-275, 1994 | 1260 | 1994 |
| Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy JE Brenman, DS Chao, H Xia, K Aldape, DS Bredt Cell 82 (5), 743-752, 1995 | 1237 | 1995 |
| Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth L Zhang, S Zhang, J Yao, FJ Lowery, Q Zhang, WC Huang, P Li, M Li, ... Nature 527 (7576), 100-104, 2015 | 1227 | 2015 |
| Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups KW Pajtler, H Witt, M Sill, DTW Jones, V Hovestadt, F Kratochwil, K Wani, ... Cancer cell 27 (5), 728-743, 2015 | 1156 | 2015 |
| Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma KPL Bhat, V Balasubramaniyan, B Vaillant, R Ezhilarasan, K Hummelink, ... Cancer cell 24 (3), 331-346, 2013 | 1153 | 2013 |
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial MR Gilbert, M Wang, KD Aldape, R Stupp, ME Hegi, KA Jaeckle, ... Journal of clinical oncology 31 (32), 4085-4091, 2013 | 1126 | 2013 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1074 | 2014 |
